MeiraGTx (Nasdaq: MGTX), has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its AAV-CNGA3 gene therapy for the treatment… Read More »MeiraGTx (NASDAQ: MGTX), a UK gene therapy company, has announced the receipt of Fast Track Designation by the FDA for the treatment of achromatopsia
Researchers at King’s College London, UK have reported that 192,986 European participants, across 10 populations, have identified 124 independent associations arising from 61 discrete genomic… Read More »A clinical study on eye colour, using genome-wide association analysis, has identified 50 previously unidentified genetic loci
Researchers based at Otto von Guericke University of Magdeburg and the Center of Behavioral Brain Sciences (CBBS), Germany, have reported results on siRNA treatment to… Read More »A novel apoptotic strategy has used siRNA to treat caspase-3 effectors protecting neuronal cells following optic nerve damage
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the May 18th, 2021 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »May 18th, 2021: “EURETINA-Brief”© Issue No. 235
Gemini Therapeutics (Nasdaq: GMTX), a US-based clinical stage ophthalmic company focused on age-related macular degeneration (AMD), has announced a Phase 2a treatment (“ReGAtta” study) and… Read More »Gemini Therapeutics (Cambridge, MA) expect to announce Phase 2a results in H12021 for dry AMD therapy.
Researchers at the Institute of Genetics, TCD, Dublin and the Department of Ophthalmology, McGill University, Montreal have reported significant research results supporting replenishment of the… Read More »Therapeutic implications reported in relation to a unique dominant RPE65 mutation with autosomal dominant retinitis pigmentosa (adRP)
Researchers at the University of Hong Kong have reported that clinicians may need to be aware of special considerations for vulnerable patients with ophthalmic conditions,… Read More »Clinicians consider how COVID19 vaccine rollout may impact outcomes for inflammatory eye disease and autoimmune disorders
Dear EURETINA Members, A very warm welcome to the March 15th, 2021 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to… Read More »March 15th, 2021: “EURETINA-Brief”© Issue No. 231
A systematic review, published in the European Journal of Ophthalmology, has reported a significant number of peer-reviewed studies on ophthalmic-focused COVID-19 articles. A study conducted… Read More »A systematic review has reported ophthalmology-focused publications and findings on COVID-19 pandemic.
A French surgical-robotics company in Montpellier, “AcuSurgical”, has announced a Series A funding of around €5.75 million for an advanced robotic microsurgical platform for the… Read More »“AcuSurgical”, a robotics company for retinal microsurgery based in Montpellier, France, has raised €5.75M funding.